247 related articles for article (PubMed ID: 24139704)
21. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes.
Luzio SD; Dunseath G; Lockett A; Broke-Smith TP; New RR; Owens DR
Diabetes Obes Metab; 2010 Jan; 12(1):82-7. PubMed ID: 19788433
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
Fink H; Herbert C; Gilor C
Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
[TBL] [Abstract][Full Text] [Related]
25. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
27. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
[TBL] [Abstract][Full Text] [Related]
28. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial.
Danne T; Datz N; Endahl L; Haahr H; Nestoris C; Westergaard L; Fjording MS; Kordonouri O
Pediatr Diabetes; 2008 Dec; 9(6):554-60. PubMed ID: 18761644
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
[TBL] [Abstract][Full Text] [Related]
30. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome.
Callesen NF; Damm J; Mathiesen JM; Ringholm L; Damm P; Mathiesen ER
J Matern Fetal Neonatal Med; 2013 Apr; 26(6):588-92. PubMed ID: 23211128
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
[TBL] [Abstract][Full Text] [Related]
32. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
[TBL] [Abstract][Full Text] [Related]
33. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
Gilor C; Ridge TK; Attermeier KJ; Graves TK
J Vet Intern Med; 2010; 24(4):870-4. PubMed ID: 20561185
[TBL] [Abstract][Full Text] [Related]
35. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
36. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
Luzio SD; Beck P; Owens DR
Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
[TBL] [Abstract][Full Text] [Related]
38. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
39. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Heise T; Pieber TR
Diabetes Obes Metab; 2007 Sep; 9(5):648-59. PubMed ID: 17645556
[TBL] [Abstract][Full Text] [Related]
40. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.
Cengiz E; Tamborlane WV; Martin-Fredericksen M; Dziura J; Weinzimer SA
Diabetes Care; 2010 May; 33(5):1009-12. PubMed ID: 20150302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
